SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ISIS?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Michael Collins who wrote (21)10/3/1996 4:25:00 PM
From: Nathan L.   of 30
 
Mike- Re: "Would you like to explain????!!!!??????"

Certainly. Let me also say that all of these concerns of yours have been fully addressed in the other Isis Pharmaceuticals forum on SI.

First off, Isis decided to lower the dosage of Fomivirsen because it is so effective that a 300 microgram dosage wasn't needed. Low dosage and low toxicity are key selling points of Antisense. That is what makes Antisense technology so appealing. Why should people who suffer from CMV retinitis be given a 300 dosage when the same results can be accomplished with a 150? Anytime a patient is given a lower dose of any drug, the risks of side-effects are decreased. The lower dosage also makes it more accessable to a larger group of people due to cost concerns.

As for the Eisai incident, i spoke with Isis management AND Eisai management personally because i was just as concerned as many others were when the news broke. Isis has stated for some time before all this happened that one major goal they had set for 1996 was to gain exclusive marketing rights for Fomivirsen. Looks to me like they succeeded.

I then spoke to Eisai and they stated that they had great interest in Fomivirsen and maintained that it is still very promising. The reason they aggreed to the new marketing agreement was because they have many R&D projects of their own going on (which they feel are just as promising) and as a new general business strategy decided to refocus and give full attention to their home-grown research.

Everything seemed to jive with me from both companies. Call them for yourself. Fomivirsen should get FDA approval towards the end of 1997 and in some cases will be used in conjunction with Chiron's CMV drug.

Also, Isis has many other drugs in developement. Check out their home page at www.isip.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News